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Background: Patients with locally advanced rectal adenocarcinoma (LARC) are treated
with neoadjuvant chemoradiotherapy (CRT). However, biomarkers for patient selection
are lacking, and the association between miRNA expression and treatment response and
oncological outcomes is unclear.
Objectives: To investigate miRNAs as predictors of response to neoadjuvant CRT and
its association with oncological outcomes.
Methods: This retrospective study analyzed miRNA expression (miR-16, miR-21,
miR-135b, miR-145, and miR-335) in pre- and post-chemoradiation rectal
adenocarcinoma tissue and non-neoplastic mucosa in 91 patients treated with
neoadjuvant CRT (50.4Gy) and proctectomy. Two groups were defined: a pathological
complete responders group (tumor regression grade—TRG 0) and a pathological
incomplete responders group (TRG 1, 2, and 3).
Results: miR-21 and miR-135b were upregulated in tumor tissue of incomplete
responders comparing with non-neoplastic tissue (p = 0.008 and p < 0.0001,
respectively). Multivariate analysis showed significant association between miR-21 in
pre-CRT tumor tissue and response, with a 3.67 odds ratio (OR) of incomplete response
in patients with higher miR-21 levels (p = 0.04). Although with no significance, patients
treated with 5-fluorouracil (5-FU) presented reduced odds of incomplete response
compared with those treated with capecitabine (OR = 0.19; 95% confidence interval (CI)
0.03–1.12, p= 0.05). Moreover, significant differences were seen in overall survival (OS) in
relation to clinical TNM stage (p= 0.0004), cT (p= 0.0001), presence of distant disease (p
= 0.002), mesorectal tumor deposits (p= 0.003), and tumor regression grade (p= 0.04).
Conclusion: miR-21 may predict response to CRT in rectal cancer (RC).
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INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent neoplasia
in the world, and rectal cancer (RC) corresponded to 30% of
all colorectal malignancies in 2019 (1). The current treatment
for patients with locally advanced rectal adenocarcinoma
(LARC) is neoadjuvant chemoradiotherapy (CRT) in order to
achieve downstaging, increase R0 resections, allow sphincter-
sparing surgery, and decrease local recurrence (LR) (2). After
neoadjuvant treatment, patients are restaged and almost 30%
develop clinical complete response (cCR) with no residual tumor
identified, 46–60% achieve some degree of tumor downstaging,
while 30% exhibit resistance to CRT (3). Non-responders are at
increased risk of disease progression and unnecessary toxicity
caused by CRT.
Recent data suggest that clinical complete responders can
safely undergo a conservative approach without surgery (4). By
contrast, the European Society for Medical Oncology (ESMO)
guidelines recommend upfront surgery in T3a-bN1 tumors if
there is no evidence of involvement of the mesorectal fascia
(2). Thus, pretreatment prediction of good and bad responders
could be important in deciding whether the patient should or
not undergo neoadjuvant CRT. Currently, although molecular
heterogeneity is a well-recognized feature of most tumors, CRC
patients are still treated based solely on clinical stage. The
inclusion of molecular markers in a treatment algorithm could
potentially stratify patients and thus allow a better choice of
candidates. No biomarkers are yet validated for selection of
patients for CRT.
MicroRNAs (miRNAs) are highly conserved non-coding
RNAs that act as post-transcriptional regulators binding a variety
of messenger RNA targets, inhibiting its translation. Although
the precise biological role of many miRNAs is yet to be entirely
elucidated, up to 30% of the human genome is regulated
by these molecules through influence in relevant cellular
functions, including stress responses, angiogenesis, metastasis,
and programmed cell death (5). Carcinogenic pathways are
regulated by miRNAs and their potential role in oncogenesis
raised the possibility of being used as biomarkers in cancer
treatment response or prediction of prognosis (6).
Althoughmost published data is on colon cancer, some studies
have addressed RC differentiating the miRNAome between
these two malignancies. Moreover, specific miRNAs have been
proposed as predictors of response to CRT in RC although
with some inconsistent findings (7–11). These results need to be
validated and are mostly related to 5-fluorouracil (5-FU)-based
therapies, not much being known about miRNAs as biomarkers
of response to capecitabine.
This study aimed to investigate miRNAs as predictors
of pathological response to CRT in RC. Based on literature
review including our own previously published data (12), five
miRNAs were chosen by virtue of having been demonstrated
to be potential biomarkers for CRC. Thus, miR-16, miR-
21, miR-135b, miR-145, and miR-335 expression was
determined and correlated with pathological response and
oncological outcomes.
MATERIALS AND METHODS
Patients and Tissue Samples
This was a retrospective study of prospectively analyzed data
and samples. Patients with RC (stages I–IV, American Joint
Committee on Cancer, AJCC) diagnosed between March 2013
and September 2017 in the Surgical Department of Hospital
Beatriz Ângelo (Loures, Portugal) treated with long course CRT
and proctectomy were eligible.
Patients had a preoperative staging with pelvic magnetic
resonance (MR), thoraco-abdomino-pelvic computed
tomography (CT), and endoanal ultrasound when pelvic
MR was not clinically possible. Histopathological features were
confirmed by pathological analysis and patients were staged
according to TNM staging system (8th edition, 2017). Patients
with other histological types of rectal malignancy, not submitted
to CRT or surgical resection, pregnant, or under the age of 18
were excluded.
Written and signed informed consent for collection and use
of biological samples was obtained from all volunteer study
participants prior to sample collection. The study protocol
conformed to the ethical guidelines of the 1975 Declaration of
Helsinki, as reflected in a priori approval by the institution’s
Human Research Committee and Ethical Committee on March
13, 2017. The study was registered in the Portuguese Data
Protection Agency.
Neoadjuvant Treatment
All patients underwent neoadjuvant CRT consisting of a 2-
Gy daily fraction of pelvic irradiation, 5 times a week, in a
total of 50.4Gy. Radiation was delivered with capecitabine (825
mg/m2/day) or 5-FU (1,000 mg/m2/day on days 1–5 and days
29–33). All patients except for one received more than 80% of
the planned radiotherapy with a curative intent. Surgery was
performed 10–12 weeks after CRT.
Assessment of Pathological Response
Pathology specimens were graded by tumor regression grade
(TRG) according to the College of American Pathologists
guidelines (CAP, TNM 7th edition). TRG was assessed by two
pathologists, blinded to patients clinical data, and categorized
as TRG 0 (no viable tumor cells or complete response), TRG
1 (single cells or little groups of cancer cells), TRG 2 (residual
cancer outgrown by fibrosis), and TRG 3 (minimal or no tumor
kill with extensive residual cancer). Tissue was retrieved from
formalin-fixed paraffin embedded (FFPE) samples. Histological
confirmation of the biopsy samples was done by pathologist
review, and neoplastic and adjacent non-neoplastic rectal tissues
were differentiated based on hematoxylin and eosin (H&E)
stain. A fixed amount of tissue (80µm) across the samples was
extracted for RNA isolation. Pre-CRT RC biopsies (colonoscopy)
were obtained from complete and incomplete responders as
well as post-CRT tumor tissues (protectomy specimen) from
incomplete responders. To allow a direct comparison of
RC to matched non-neoplastic rectal mucosa, we collected
adjacent (>1 cm distant) non-tumor tissue in both biopsies and
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TABLE 1 | Patient clinical parameters.
Clinical parameters Patients (n = 91)
Gender, n (%) Male 60 (66)
Female 31 (34)
Age, median 68 (45–83)
BMI, median 26 (15–45)





Grade G1/G2 85 (93)
G3/G4 6 (7)
Location (%) 1/3 superior 19 (21)
1/3 medium 28 (31)
1/3 inferior 44 (48)
Tumor extension (mm), median 58 (5–120)
Distance to anal verge (mm), median 60 (0–130)




cN 0 9 (10)
+ 82 (90)
cM 0 78 (86)
1 13 (14)
CRM, n (%) Free 67 (74)
Threatened or invaded 24 (26)
EMVI, n (%) Negative 86 (95)
Present 5 (5)




CEA (mg/mL) 1.9 (0.5–163)
Chemotherapy Capecitabine based 83 (91)
5-FU based 8 (9)




BMI, Body Mass Index; ASA, American Society of Anaesthesiologists; CRM,
circumferential resection margin; EMVI, extramural vascular invasion; CEA,
carcinoembrinonary antigen; TRG, tumor regression grade; CAP, College of
American Pathologists.
protectomy specimens. Two groups of patients were defined,
including a pathological complete responders group (TRG 0) and
a pathological incomplete responders group (TRG 1, 2, and 3).
RNA Isolation
For total RNA isolation, pre- and post-CRT FFPE non-neoplastic
and tumor rectal tissue samples were first deparaffinized with
xylene (VWR International, Radnor, PA, USA) in two washing
steps at 50◦C. The samples were then fully homogenized into
fine particles in 100% ethanol using a motor-driven grinder
and centrifuged at maximum speed for 5min. The collected
pellet was rehydrated with 95% ethanol for 10min following
a new centrifugation step at maximum speed for 5min. Then,
samples were lysed with 500µg/mL proteinase K in 100 µL of
protease digestion buffer (20mM Tris–HCl pH 8.0, 1mM CaCl2
0.5% SDS) at 55◦C. Total RNA was isolated using RibozolTM
reagent (VWR International, Radnor, PA, USA) according to
the manufacturer’s instructions and eluted into 20 µL RNase-
free water. For a better evaluation of miRNAs quantity in
total RNA, the miRNA concentration was determined using
QubitTM miRNA Assay kit (Invitrogen, Thermo Fisher Scientific,
Waltham, MA, USA).
Expression Analysis by Real-Time PCR
(RT-PCR)
cDNA synthesis was performed using TaqMan R© Advanced
miRNA cDNA synthesis kit (Applied Biosystems, Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s
instructions. For a uniform quantification of the quantity of
miRNA to be used in cDNA, 2 µL of total RNA (corresponding
to 2 ng of RNA) was extended by a 3′ poly-A tailing reaction
and a 5′ adaptor ligation to the mature miRNAs. miRNAs
were reverse transcribed into cDNA by reverse transcription
using Universal RT primers. In order to improve detection
of low-expressing miRNA targets, a pre-amplification of the
cDNA was performed using the Universal miR-Amp Primers
and miR-Amp Master Mix to uniformly increase the amount
of cDNA for each target, maintaining the relative differential
expression levels. cDNA samples were stored at −20◦C. Real-
time polymerase chain reaction (PCR) was performed on
a QuantstudioTM 7 Flex real-time PCR instrument (Applied
Biosystems, Thermo Fisher Scientific, Waltham, MA, USA) with
TaqManTM Advanced microRNA Assays (Applied Biosystems,
Thermo Fisher Scientific, Waltham, MA, USA) to assess the
expression profile of hsa-miR-16-5p (Assay ID 477860_mir), hsa-
miR-135b-5p (Assay ID 478582_mir), hsa-miR-145-5p (Assay ID
477916_mir), hsa-miR-335-5p (Assay ID 478324_mir), and hsa-
miR-21-5p (Assay ID 477975_mir). All reactions were performed
in duplicate.
Due to the fact that a consensual endogenous control for miR
expression in rectal tissue has still not been determined, initial
preliminary analyses were performed to test several miRNAs as
controls. Normalization was then performed with hsa-miR-484
(Assay ID 478308_mir), identified as the most stably expressed
miRNA with the lowest expression variability between samples
in these patient data set when compared with mir-1228-5p, miR-
345-5p, and miR-103a-3p and the small nuclear (snRNA) U6 and
RNU6B, some considered controls for CRC tissues. Expression
levels were calculated by the threshold cycle (2−11Ct method)
where 11Ct = (Ct target miR − Ct control) sample − (Ct
target miR − Ct control) median, when amplification values
were detected in the real-time PCR. Due to lack of amplification
values detected by the real-time PCR in all patient tissues,
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FIGURE 1 | Expression profile of miR-21, miR-135b, miR-145, miR-16, and miR-335 in pre- and post-CRT non-neoplastic and tumor tissues in incomplete (TRG 1 +
2 + 3) and complete responders (TRG 0). Pre-CRT non-neoplastic tissue samples used in this study were derived from a maximum of 37 and 10 patients in TRG 1 +
2 + 3 and TRG 0 groups, respectively. Pre-CRT tumor tissue and post-CRT tissue samples were analyzed from a maximum of 76 patients (TRG 1 + 2 + 3) and 15
patients (TRG 0). Data are mean ± SEM (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001), in which N corresponds to non-neoplastic tissue and T to tumor tissue.
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TABLE 2 | Association between miRNA expression and TRG.
Variables OR 95% CI p-Value
miR-21 ≤0.66 1.00
Pre-CRT non-neoplastic >0.66 1.428 0.32–6.79 0.6407
miR-21 ≤1.18 1.00
Pre-CRT tumor >1.18 3.58 1.13–12.65 0.0346
miR-135b ≤0.8 1.00
Pre-CRT non-neoplastic >0.8 1.85 0.40–10.27 0.4420
miR-135b ≤1.01 1.00
Pre-CRT tumor >1.01 2.33 0.58–11.62 0.25
miR-145 ≤1.28 1.00
Pre-CRT non-neoplastic >1.28 0.65 0.11–5.18 0.643
miR-145 ≤0.73 1.00
Pre-CRT tumor >0.73 0.88 0.26–3.02 0.838
miR-16 ≤0.77 1.00
Pre-CRT non-neoplastic >0.77 2.00 0.44–10.80 0.3806
miR-16 ≤0.54 1.00
Pre-CRT tumor >0.54 1.75 0.49–6.19 0.375
miR-335 ≤1.16 1.00
Pre-CRT non-neoplastic >1.16 4.5 0.64–91.58 0.191
miR-335 ≤1.01 1.00
Pre-CRT tumor >1.01 1.86 0.49–7.24 0.354
Simple logistic regression using miRNA dichotomized according to cut-offs
determined with ROC curve analysis. OR, odds ratio of incomplete/non-response; CI,
confidence interval.
a variable number of samples were included in each miRNA
expression profile.
Statistical Analysis
The estimated sample size was 86 patients (43 patients per group
of low and high miR expression). Sample size was calculated with
an estimated proportion of patients TRG 0 with high and low
miR-21 expression of 0.067 and 0.35, respectively. Type I and II
errors were set at α = 0.05 and β = 0.2, respectively. miRNA
expression was analyzed using the GraphPad Prism software
package, version 7.0 (GraphPad software Inc., San Diego, CA,
USA). Normal distribution was determined using the D’Agostino
and Pearson omnibus test. Data was analyzed according to
normality of values distribution using the one-way analysis of
variance (ANOVA) followed by Kruskal–Wallis non-parametric
Dunn’s multiple comparison test or ANOVA Tukey’s multiple
comparisons test according to Gaussian distribution.
Receiver operating characteristic curve (ROC) analysis was
then conducted, establishing the optimal cutoffs for each miRNA
before CRT in non-neoplastic and tumor tissue, determined
as the point closest to the top left part of the plot with
perfect sensibility and sensitivity. All miRNAswere dichotomized
according to these cutoffs. Further analysis was also performed
to explore the best discriminative cutoff point for miR-21 by
comparing the cutoff determined in this study (1.18) with
the previously reported miR-21 cutoff (2.8) (13). Both cutoffs
presented a similar area under the curve (AUC), with our cutoff
having an AUC value of 0.65 (95% CI = 0.518–0.790), a higher
specificity (66 vs. 60%), a lower sensitivity (64 vs. 87%), a similar
positive predictive value (PPV) (92 vs. 90%) and a lower negative
predictive value (NPV) (29 vs. 43%) (Supplementary Figure 1
and Supplementary Table 1). Although both dichotomizations
presented similar performance, we chose the cutoff determined
in this study that yielded a better-distributed categorization
of miR-21.
Simple and multiple logistic regressions were used to correlate
each variable with the outcome response after CRT: “pathological
complete response (TRG 0)” or “pathological incomplete
response (TRG 1, 2, and 3).” For continuous variables, linearity
of the logit in the predictor was assessed using a cubic spline and
Wald test of linearity.
The association between high and low miR-21 expression
and clinical characteristics was tested with chi-square test. Only
variables with p≤ 0.25 in simple logistic regression or considered
clinically relevant were selected to multiple logistic regression.
Multicollinearity was also analyzed through the observation of
variance inflation factors. A stepwise both-selection technique
was used to create the multiple regression model. ROC curve
was computed and the respective AUC was calculated to assess
discriminatory ability of the model.
RESULTS
Patient Clinical Parameters
Demographic and clinical parameters of the 91 patients are
summarized in Table 1. With 4 patients lost (4.4%), median
follow up was 4.2 years.
miRNA Expression in Complete and
Incomplete Responders
miRNA expression profiles were analyzed in non-neoplastic and
tumor rectal tissue before and after CRT in all 91 patients.
Significant changes were observed when comparing incomplete
and complete responders (Figure 1). In incomplete responders,
miR-21 revealed higher expression in pre-CRT tumor tissue in
comparison with non-neoplastic tissue (p = 0.03). Post-CRT
samples also presented higher levels of miR-21 in tumor tissue
(p= 0.008). In contrast, in complete responders, miR-21 showed
similar levels in pre-CRT tumor and non-neoplastic tissue.
miR-135b presented a profile equivalent to miR-21. In
incomplete responders, miR-135b upregulation was detected in
tumor tissue, either pre- or post-CRT (p < 0.0001), whereas in
complete responders equal levels were found in pre-CRT tumor
samples and non-neoplastic tissue. AlthoughmiR-145 expression
showed significant differences among pre- and post-CRT non-
neoplastic and tumor tissues (p < 0.0001) in incomplete
responders, similar results were detected in complete responders,
suggesting a lack of discriminative value of this miRNA.
Moreover, there were no significant differences in miR-16 and
miR-335 expression between groups. Thus, these results suggest
that miR-21 and miR-135b might be useful biomarkers to predict
treatment response.
Identification of miRNAs Involved in TRG
The significantly different expression of miRNAs between
incomplete (TRG 1, 2, and 3) and complete responders (TRG
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TABLE 3 | Clinical parameters and TRG in miR-21 expressing patients.
Simple logistic regression TRG 0 n = 15 TRG 1 + 2 + 3 n = 67 OR 95% CI p-Value
Continuous variables Median (Max–Min) Median (Max–Min)
Age 67.0 (53–81) 68 (45.0–83) 1.00 0.94–1.06 0.976
Weight 70.0 (45–113) 68 (44.0–119) 0.99 0.96–1.03 0.645
BMI 25.0 (19–41) 26 (15.0–45) 1.00 0.91–1.13 0.921
Tumor extension (mm) 54.5 (21–110) 56 (5–120) 0.99 0.97–1.03 0.901
CEA 2.8 (0.5–8.3) 1.9 (0.5–163) 1.07 0.99–1.29 0.299
Weeks post-chemo 11 (7.0–28) 10 (2.0–21) 0.87 0.73–1.01 0.081
Categorical variables Number Number
Gender Male 11 45 1.00
Female 4 22 1.34 0.41–5.29 0.643
Tumor location 0 3 14 1.00
1 8 16 0.43 0.08–1.81 0.271
2 4 37 1.98 0.35–10.13 0.407
ASA 1 + 2 9 54
3 + 4 6 13 0.36 0.11–1.24 0.0955
CRM MR Free 11 50 1.00
Threatened 1 4 0.88 0.12–18.11 0.913
Invaded 3 13 0.95 0.25–4.66 0.947
Extramesorectal nodes Negative 12 43 1.00
Positive 3 24 2.23 0.63–10.50 0.247
cT 1 + 2 1 8 1.00
3 + 4 14 59 0.53 0.03–3.23 0.561
cN 0 2 6 1.00
1 13 61 1.56 0.21–7.721 0.608
cM 0 14 57 1.00
1 1 10 2.46 0.42–46.96 0.41
Stage I 1 2 1.00
II 2 5 1.25 0.04–23.53 0.880
III 11 51 2.32 0.10–26.38 0.508
IV 1 9 4.50 0.14–156.82 0.352
Stage I + II 3 7 1.00
III + IV 12 60 2.14 0.42–8.99 0.315
Chemotherapy Capecitabine 12 64 1.00
5-FU 3 3 0.188 0.03–1.12 0.05
Simple logistic regression analysis using TRG as dependent variable and clinical/molecular variables as independent variables. From the initial group of 91 patients,
82 expressed miR-21.
TRG, Tumor regression grade; OR, odds ratio of incomplete response; CI, confidence interval; BMI, body mass index; CEA, carcinoembrionary antigen; ASA, American Society of
Anaesthesiologists; CRM, circumferential resection margin; MR, magnetic resonance.
0) suggested a possible association between miRNA expression
and treatment response. The relation between miRNA in
pre-CRT samples and response was analyzed with logistic
regression (Table 2). A significant association was found between
miR-21 in pre-CRT tumor tissue and TRG. Patients with
expression higher than 1.18 (fold change) were 3.58 more
likely to obtain an incomplete response than those with
expression lower than 1.18 (p = 0.03). However, there was
no association between pre-CRT non-neoplastic or tumor
tissue expression of miR-135b and TRG. The same was found
for miR-16, miR-145, and miR-335. Given the association
of miR-21 and response, we proceeded with the study of
this miRNA.
Clinical Parameters and TRG in miR-21
Expressing Patients
From the initial group of 91 patients, only 82 patients expressed
miR-21 due to lack of amplification. Although with no significant
association between type of radio-sensitizing agent and TRG,
patients treated with 5-FU presented reduced odds ratio (OR)
of incomplete response compared with patients treated with
capecitabine [OR = 0.19; 95% confidence interval (CI) 0.03–
1.12, p = 0.05]. It was also recognized a definitive trend toward
reduced odds of incomplete response with longer waiting times
(OR = 0.87; 95% CI 0.73–1.01, p = 0.08). However, there was
no association between patient gender, age, weigh, American
Society of Anaesthesiologists (ASA) score, body mass index
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TABLE 4 | Clinical parameters and levels of miR-21 expression.
Variables Number (%) High miR-21 Low miR-21 p-Value
miR-21 pre-CRT tumor 82 (100) 48 (58.5) 34 (41.5)
Age <60 15 (18.3) 7 (14.6) 8 (23.5) 0.302
≥60 67 (81.7) 41 (85.4) 26 (76.5)
Sex Male 56 (68.3) 32 (66.7) 24 (70.6) 0.707
Female 26 (31.7) 16 (33.3) 10 (29.4)
BMI Low weight 1 (1.2) 0 (0) 1 (2.9) 0.236
Normal 27 (32.9) 17 (35.4) 10 (29.4)
Pre-obesity 39 (47.6) 25 (52.1) 14 (41.2)
Obesity 15 (18.3) 6 (12.5) 9 (26.5)
ASA score 1 2 (2.4) 1 (2.1) 1 (2.9) 0.330
2 53 (64.6) 29 (60.4) 24 (70.6)
3 18 (22) 11 (22.9) 7 (20.6)
4 1 (1.2) 1 (2.9) 0 (0)
ND 8 (9.8) 7 (14.6) 1 (2.9)
Stage pre-CRT I 3 (3.7) 1 (2.1) 2 (5.9) 0.720
II 7 (8.5) 4 (8.3) 3 (8.8)
III 62 (75.6) 36 (75.0) 26 (76.5)
IV 10 (12.2) 7 (14.6) 3 (8.8)
Stage post-CRT 0 12 (14.6) 6 (12.5) 6 (17.6) 0.607
I 6 (7.3) 4 (8.3) 2 (5.9)
II 6 (7.3) 5 (10.4) 1 (2.9)
III 9 (11.0) 4 (8.3) 5 (14.7)
IV 3 (3.7) 1 (2.1) 2 (5.9)
NA 5 (6.1) 4 (8.3) 1 (2.9)
ND 41 (50) 24 (50.0) 17 (50.0)
Grade pre-CRT Low 77 (93.9) 45 (93.8) 32 (94.1) 1.00
High 5 (6.1) 3 (6.2) 2 (5.9)
cT 1 1 (1.2) 1 (2.1) 0 (0.0) 0.852
2 8 (9.8) 5 (10.4) 3 (8.8)
3 59 (72.0) 34 (70.8) 25 (73.5)
4 14 (17.1) 8 (16.7) 6 (17.6)
cN 0 8 (9.8) 4 (8.3) 4 (11.8) 0.606
1 74 (90.2) 44 (91.7) 30 (88.2)
cM 0 71 (86.6) 41 (85.4) 30 (88.2) 0.712
1 11 (13.4) 7 (14.6) 4 (11.8)
pTRG TRG 0 15 (18.3) 5 (10.4) 10 (29.4) 0.064
TRG 1 21 (25.6) 16 (33.3) 5 (14.7)
TRG 2 32 (39.0) 20 (41.7) 12 (35.3)
TRG 3 14 (17.1) 7 (14.6) 7 (20.6)
Distant recurrence No 60 (73.2) 33 (68.8) 27 (79.4) 0.283
Yes 22 (26.8) 15 (31.2) 7 (20.6)
Local recurrence No 75 (91.5) 43 (89.6) 32 (94.1) 0.694
Yes 7 (8.5) 5 (10.4) 2 (5.9)
Death No 61 (74.4) 33 (68.8) 28 (82.4) 0.164
Yes 21 (25.6) 15 (31.2) 6 (17.6)
From the initial group of 91 patients, 82 expressed miR-21.
ASA, American Society of Anaesthesiologists; BMI, body mass index; CRT, chemoradiotherapy; pTRG, pathological tumor regression grade.
(BMI), tumor location, tumor extension, histological grade,
pre-therapeutic carcinoembrionary antigen (CEA), radiological
involvement of the circumferential resection margin (CRM),
presence of extramural vascular invasion (EMVI), mesorectal
deposits (N1c), extramesorectal nodes, cT, cN, cM, stage (TNM,
AJCC), and TRG (Table 3).
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TABLE 5 | Association between clinical parameters and TRG.
Variables OR 95% CI p-Value
Stage 1 + 2 1.00
3 + 4 2.16 0.388–10.16 0.341
miR-21 ≤1.18 1.00
>1.18 3.67 1.126–13.49 0.036
ASA score 1 + 2 1.00
3 + 4 0.33 0.090–1.185 0.082
Multiple logistic regression analysis using TRG as dependent variable and disease stage,
miR-21 and ASA score as independent variables.
OR, odds ratio; CI, confidence interval; ASA, American Society of Anaesthesiologists.
Clinical Parameters and Levels of miR-21
Expression
Although no statistically significant association between clinical
parameters and expression of miR-21 was observed, a near
significant association was established between this miRNA and
TRG, with higher proportion of incomplete response in patients
with higher miR-21 levels (p = 0.06) (Table 4). In multivariate
analysis, after adjustment for clinically and statistically relevant
variables (disease stage and ASA score), this association was
again demonstrated with odds of incomplete response 3.67 times
greater in individuals with a miR-21 overexpression (>1.18-fold
change) when compared with those with lower miR-21 levels
(≤1.18-fold change) (95% CI 1.13–13.5; p= 0.04) (Table 5).
Oncological Outcomes
Overall survival (OS) at 2 and 5 years was 90% (95%CI 83.4–96.9)
and 72% (95% CI 61.6–85.1), respectively. Overall disease-free
survival (DFS) at 2 and 5 years was 74.1% (95% CI 64.4–84.8)
and 66% (95% CI 55–80), respectively (Figure 2).
Overall survival was not influenced by age, gender, tumor
location, grade, mesorectal nodes, extramesorectal nodes, type of
radio-sensitizing agent, post-operative complications, and levels
of miR-21 (p= 0.36) (Figure 3 and Supplementary Figure 2). As
expected, there was an impact in OS in relation to T (p < 0.0001)
mesorectal tumor deposits, N1c (p = 0.003), distant metastasis
M (p = 0.002), stage (p = 0.0004), and TRG (p = 0.04) with a
borderline significance for threatened circumferential resection
margin, CRM (p = 0.05) (Figure 3). Also, there was increase
death risk in individuals with higher cT (HR= 4.78; 95%CI 1.96–
11.66, p = 0.0006), higher stage (HR = 11.1; 95% CI 1.34–91.88,
p= 0.03), threatened mesorectal fascia (HR= 4.24; 95% CI 1.19–
15.08, p = 0.03), positive N1c (HR = 5.47; 95% CI 1.56–19.14, p
= 0.008), distant metastasis (HR = 3.78; 95% CI 1.52–9.4, p =
0.004), and TRG 3 (HR= 3.25; 95% CI 0.83–12.71, p= 0.08). No
association was, however, established between miR-21 expression
and risk of death (Table 6).
Finally, the utility of miR-21 as a predictor of survival was
investigated. The model of prediction, in multivariate analysis,
adjusted to the most relevant clinical variables, did not show a
significant association between risk of death and higher miR-21
expression (HR= 2.68; 95% CI 0.86–8.36, p= 0.09) (Table 7).
DISCUSSION
Rectal cancer (RC) patients treated with CRT urgently need
biomarkers to distinguish responders from non-responders
and allow individualized treatment, with non-responders
avoiding neoadjuvant therapy and complete responders eluding
mutilating resections. In this work, we investigated five miRNAs
as biomarkers to predict response to CRT in RC.
miR-145 and miR-335 are acknowledged to act as tumor
suppressor genes (14, 15) and miR-145 is overexpressed in post-
CRT tumor tissue in comparison with pre-CRT with significant
correlation with tumor regression (7). In our work, no differences
were detected in these miRNAs before and after CRT and no
correlation was found with response. In addition, miR-16 has
been described as a tumor suppressor with downregulation
predicting poor prognosis in CRC (16). In our study, miR-
16 was not a predictor of response either. miR-135b is an
oncomiR that often mediates CRC genes whose overexpression
has been correlated with tumor stage and poor clinical outcome
(17). We have further analyzed its potential as predictor of
response to CRT and found significant differences in expression.
In incomplete responders, higher miR-135b levels were found
in both pre- and post-CRT tumor tissues comparing with
non-neoplastic tissues, whereas in complete responders similar
expression was obtained in all samples. We could not, however,
correlate miR-135b expression with clinical parameters or TRG.
Finally, in our study we found that incomplete responders
had higher miR-21 expression in tumor tissue in comparison
with non-neoplastic tissue in both pre- and post-CRT samples.
In contrast, complete responders had similar levels in all samples.
Moreover, an association was discovered between pre-CRT
tumor miR-21 levels and TRG, with a 3.67 odds of non-response
in patients with expression higher than 1.18 (p = 0.04). Higher
miR-21 expression in the tumor prior to treatment was indicative
of a worst response. As expected, OS was influenced by cT,
cM, N1c, TRG, and threatened CRM but no association was
noted between risk of death and miR-21 expression. Thus, in
this study, we showed that miR-21 expression levels before
neoadjuvant therapy had the potential to predict response and
that patients with miR-21 overexpression exhibited less response
to standard CRT dose. This did not, however, translate in a
change in survival.
miR-21 is often upregulated in solid tumors influencing cell
proliferation, invasion, and apoptosis (18). Considered to be
an oncomiR, multiple studies report its role in CRC biology
as a screening, diagnostic, and prognostic biomarker (6, 19–
23). Also, miR-21 upregulation has been related to advanced
stage, presence of positive lymph nodes, venous invasion, and
metastatic behavior (24, 25).
In contrast to colonic cancer, very limited data is available on
miRNA expression and response to CRT in RC (26–28) withmost
patients treated with 5-FU-based therapies and not capecitabine.
So far, miR-21 has been described to induce resistance to 5-FU
when overexpressed in colon cancer cells (13, 29), which could
eventually explain its effect regarding 5-FU-based CRT response.
Literature is controversial regarding the use of miR-21 as
biomarker of response in RC. In one study with 76 RC
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FIGURE 2 | Patient outcomes in miR-21-expressing patients. Kaplan–Meier curves for overall survival and disease-free survival.
FIGURE 3 | Overall survival according to clinical and oncological parameters. Kaplan–Meier curves estimating overall survival according to stage, mesorectal tumor
deposits (cN1c), M, stage, circumferential resection margin (CRM) involvement, tumor regression grade and levels of miR-21.
biopsies, high pre-CRT miR-21 could discriminate responders
from non-responders with an OR of 9.75 (95% CI 2.24–42)
(30). Recently, 96 complete responders had significantly inferior
miR-21 expression comparing with patients with incomplete
response (p = 0.01), with an AUC of 0.669 (95% CI 0.55–
0.79, p = 0.01) (31). These observations are in accordance
with our own results and with the well-reported miR-21
oncomiR function. Contrarily, in another study, 40 RC patients
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TABLE 6 | Patient survival according to miR-21 expression and clinical parameters.
Patients n = 82 Deaths n = 21 Survival Simple cox proportional hazards models
Mean p-Value Coef HR 95% CI p-Value
miR-21 <1.18 34 6 6.04 1.00 0.36
≥1.18 48 15 5.50 0.36 0.44 1.56 0.60–4.03
Age <60 17 3 5.81 0.58 1.00 0.57
>60 65 18 5.51 0.35 1.42 0.41–4.8
Sex Male 56 16 5.56 0.57 1.00 0.57
Female 26 5 5.82 −0.29 0.75 0.27–2.04
Tumor location 1/3 upper 17 3 6.09 0.14 1.00
1/3 middle 24 5 6.13 0.05 1.045 0.25–4.40 0.94
1/3 lower 41 13 5.16 0.91 2.49 0.70–8.85 0.158
ASA score 1 + 2 55 14 5.71 0.97 1.00
3 + 4 19 5 5.44 0.10 1.11 0.39–3.094 0.879
ND 8 2 5.10 0.12 1.12 0.25–4.99 0.986
Stage I+II 10 1 6.32 0.0004 1.00
III 61 13 5.74 0.83 2.31 0.30–17.65 0.4218
IV 11 7 3.54 2.41 11.10 1.34–91.88 0.0256
Grade Low 77 19 5.74 0.41 1.00
High 5 2 4.87 0.60 1.83 0.42–7.88 0.42
CRM Free 61 14 5.91 0.051 1.00
Threatened 5 3 3.77 1.45 4.24 1.19–15.08 0.025
Invaded 16 4 5.47 0.51 1.67 0.54–5.142 0.37
EMVI Negative 77 20 4.45 0.77 1.00 0.768
Positive 5 1 4.20 0.31 1.36 0.17–10.41
N1c Negative 78 18 5.15 0.0028 1.00 0.00788
Positive 4 3 2.98 1.69 5.47 1.56–19.14
Extramesorectal nodes Negative 55 13 5.77 0.26 1.00
Positive 27 8 5.15 0.51 1.67 0.68–4.07 0.263
cT T1-3 68 13 6.05 0.0001 1.00
T4 14 8 3.73 1.56 4.78 1.96–11.66 0.0006
cN 0 8 1 6.25 0.42 1.00
1 74 20 4.48 0.81 2.24 0.29–16.7 0.432
cM 0 71 14 5.98 0.0021 1.00
1 11 7 4.02 1.33 3.78 1.52–9.4 0.00416
TRG 0 15 3 5.94 0.047 1.00
1 21 3 6.32 0.49 0.61 0.12–3.05 0.5504
2 32 8 5.54 0.34 1.41 0.37–5.35 0.6130
3 14 7 4.31 1.18 3.25 0.83–12.71 0.0897
Chemotherapy Capecitabine 76 19 5.24 0.47 1.00
5-FU 6 2 4.83 0.54 1.71 0.39–7.43 0.476
Post-op complications Negative 38 9 5.85 0.6 1.00
Positive 44 12 5.55 0.23 1.26 0.53–0.98 0.604
Kaplan–Meier estimates, simple cox proportional hazards model. From the initial group of 91 patients, 82 expressed miR-21.
HR, hazard ratios; CI, confidence interval; ASA, American Society of Anaesthesiologists; CEA, carcinoembrionary antigen; CRM, circumferential resection margin; EMVI, extramural
vascular invasion; TRG, tumor regression grade.
treated with 5-FU-based CRT had higher miR-21 in post-
CRT tumor tissue than in pre-CRT tumor and post-CRT
normal tissues (7). It has also been reported overexpression
of miR-21 in patients with complete response (32, 33). It
is important to note, however, that in one of these studies,
the responder group involved a different set of patients,
including individuals submitted to surgery with pathological
complete response (pCR) and patients with complete clinical
response (cCR) not treated with surgery but only observed
by follow up (33). The latest might have had undetectable
residual disease and not be a real pCR. This different response
assessment invalidates an accurate comparison of results and
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TABLE 7 | Association between patients survival and miR-21 expression.
Multiple cox proportional hazards models Multiple cox proportional hazards models
Coef HR 95% CI p-Value Coef HR 95% CI p-Value
miR-21 <1.18 Not included 1.00
≥1.18 0.99 2.68 0.86–8.36 0.089
Mesorectal deposits Negative 1.00 1.00
Positive 1.84 6.26 1.74–22.48 0.005 2.49 12.17 2.61–56.70 0.001
cT T1-3 1.00 1.00
T4 1.63 5.09 2.06–12.61 0.0004 1.69 5.45 2.17–13.63 0.0003
C-statistics 0.671 0.674
Multiple Cox Proportional Hazards Models obtained with stepwise variable selection.
HR, hazard ratios; CI, confidence interval.
may explain the distinct observations when compared with
our work.
Overall, the heterogeneity of results is related to the fact that
most published studies included patients with colon and RC, 2
distinct entities with different treatment strategies that previous
contributions failed to separate. Patient variability, nature of
biological samples (blood, tissue, serum, or feces), miRNA
extraction, array platforms, bioinformatics analysis, and different
TRG grading systems also contribute to these discrepancies.
Likewise, it is possible that populationmay have different miRNA
signatures and transcriptome vary according to tumor site.
In this study, we recognized the significance of miR-21
expression in RC in response to neoadjuvant CRT. Although
including a sizeable cohort with uniform sampling and
treatment, there is a potential for intratumoral heterogeneity
and results are currently being validated in a prospective series.
If confirmed as a biomarker, translation to clinical practice
with miR-21 inclusion in treatment algorithms may allow a
stratification of responders and better selection of candidates
for CRT.
Of note, in addition to possible markers of response
and prognosis at the time of diagnosis, miRNAs may be
potential therapeutic targets via reintroducing miRNAs absent
in carcinogenic pathways or by inhibiting oncomiRs (34–36).
Likewise, affecting miRNAs implicated in the mechanism of
resistance to CRT may improve the therapeutic outcome. The
biggest challenge will continue to be the identification of miRNA
targets that shed light on our understanding of downstream
cellular mechanisms of resistance to CRT.
In conclusion, the present study suggests miR-21 as a potential
biomarker of pathological response in RC. The results provide
an association between a miRNA in the neoadjuvant therapy
setting and tumor regression with significant implications that
strengthen the role of miRNAs as predictors of response. This
work further emphasizes the need for prospectively conducted
trials of miRNA as biomarkers in RC patients treated with CRT.
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